Syndax Pharmaceuticals, Inc. Common Stock, Capital Shares Reserved for Future Issuance
Syndax Pharmaceuticals, Inc. (SNDX) had Common Stock, Capital Shares Reserved for Future Issuance of 30.34 million shares as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes
us-gaap:CommonStockCapitalSharesReservedForFutureIssuance · last filed 2026-02-26
- 2025-12-31: Common Stock, Capital Shares Reserved for Future Issuance 30.34M shares.
- 2024-12-31: Common Stock, Capital Shares Reserved for Future Issuance 27.18M shares.
- 2023-12-31: Common Stock, Capital Shares Reserved for Future Issuance 23.91M shares.
- 2022-12-31: Common Stock, Capital Shares Reserved for Future Issuance 11.58M shares.
| Period end | Common Stock, Capital Shares Reserved for Future Issuance |
|---|---|
| 2025-12-31 | 30.34M shares 10-K · filed 2026-02-26 |
| 2024-12-31 | 27.18M shares 10-K · filed 2025-03-03 |
| 2023-12-31 | 23.91M shares 10-K · filed 2024-02-27 |
| 2022-12-31 | 11.58M shares 10-K · filed 2023-02-28 |
| 2021-12-31 | 13.34M shares 10-K · filed 2022-03-01 |
| 2020-12-31 | 11.61M shares 10-K · filed 2021-03-12 |
| 2019-12-31 | 16.60M shares 10-K · filed 2020-03-05 |
| 2018-12-31 | 8.33M shares 10-K · filed 2019-03-07 |
| 2017-12-31 | 5.50M shares 10-K · filed 2018-03-08 |
| 2016-12-31 | 4.64M shares 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |